Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
FDA expanded EVO/EVO+ age indication, preliminary Q1 sales exceeded $90M with China rebound and Americas growth, Q1 results due 2026-05-13, and shares remain up about 32% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Failed rebound ⢠Support test Support Level: $23.4-$24.0 Resistance Level: $26.4, then $28.0-$29.0 STAA has rolled from a strong uptrend into a clear downtrend over the last month, with lower highs/lows, a failed rebound, and a fresh low at $23.38, so traders should watch the $23.4-$24.0 support while treating $26.4 and then $28.0-$29.0 as key recovery hurdles.
Sentiment & News
Key News Insights: ⢠Revenue growth ⢠Guidance gap ⢠Regional headwinds STAAR Surgical's preliminary Q2 sales topped $90M and surged vs. last year, but the stock fell as investors focused on missing guidance and EMEA/geopolitical risks.
AI Summary
STAA has shifted from a slow-growth medtech name to a genuine turnaround story, but the sharp selloff after the >$90M Q2 sales update shows investors need proof that the revenue surge converts into durable margin and cash-flow inflection before rerating the stock.
Description
STAAR Surgical Company designs, manufactures and sells implantable intraocular lenses and the delivery systems used to place them, along with preloaded cataract lenses, injector components and related surgical instruments. Its products, which address refractive errors and cataract treatment, are marketed primarily to ophthalmologists and surgical centers through a mix of direct sales forces and distributor networks across North America, Europe and Asia. The company was founded in 1982 and is headquartered in Lake Forest, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | STAA | STAAR Surgical Company | FDA expanded EVO/EVO+ age indication, preliminary Q1 sales exceeded $90M with China rebound and Americas growth, Q1 results due 2026-05-13, and shares remain up about 32% over 21 trading days. | Closed | +5.9% |
| Apr 10 | Apr 17 | STAA | STAAR Surgical Company | STAAR Surgical has a fresh revenue surprise and momentum: preâannounced Q1 net sales above ~$90M drove a ~25% twoâday spike, and FDA expansion of EVO/EVO+ ICL indication (21â60 years) broadens its market. Shares are ~42% above their 21âday mean, with strong volume and activist/institutional buying, making STAA a highâvelocity nearâterm trade around the formal earnings release. | Closed | -5.1% |